|
|
|
28.05.25 - 18:03
|
ABIONYX Pharma Provides an Update on Its Activity and Cash Position for the 1st Quarter 2025 (Business Wire)
|
|
|
Consolidated sales of 1 M€ at end March 2025
Cash position of 4.1 M€ at March 31, 2025 before collection of Research Tax Credit of 1.08 M€
Anticipated key milestone: feedback from the EMA by the end of 2025 on the clinical results of LCAT patients treated with a view to marketing authorization
TOULOUSE, France & LAKELAND, Mich.--(BUSINESS WIRE)--Regulatory News:
ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world's only natural recombinant apoA-I, today provides an update on its activity and cash position as of March 31, 2025.
Selected financial information (IFRS)
€m
Q1 2024
Q1 2023
Revenue from biotech activity
0.00
0.00
Revenue from IRIS Pharma
0.99
1.40
Total revenue
0.99
1.40
Other revenue
0.00
0.00
Total revenue income and revenue
0.99
1.40
Cash and cash equivalents at the end of the pe
4.09
2.70
ABIONYX Pharma recorded consolidated quarterly sales of nearly €1 millio...
|
|
|
06.05.25 - 21:36
|
ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company′s Share Capital (Business Wire)
|
|
|
Article L233-8-II of the French Commercial Code
Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority)
PARIS--(BUSINESS WIRE)--Regulatory News:
ABIONYX Pharma (Paris:ABNX):
Market: Euronext Paris, Compartment C
ISIN code: FR0012616852
Date
Number of shares outstanding
Total voting rights
Total gross (1)
Total net (2)
April 30, 2025
34,931,012
44,381,742
44,073,317
(1) The total number of gross (or “theoretical”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.
(2) The total number of net (or “exercisable at a Shareholders' Meeting”) voting rights is calculated without taking into account shares for which voting rights have been suspended. It is released in order to ensure that the public is properly informed, in accordance wit...
|
|
|
03.04.25 - 20:18
|
ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company′s Share Capital (Business Wire)
|
|
|
Article L233-8-II of the French Commercial CodeArticle 223-16 of the General Regulations of the AMF (French Financial Markets Authority)
PARIS--(BUSINESS WIRE)--Regulatory News:
ABIONYX Pharma (Paris:ABNX):
Market: Euronext Paris, Compartment C
ISIN code: FR0012616852
Date
Number of shares outstanding
Total voting rights
Total gross (1)
Total net (2)
March 31, 2025
34,931,012
44,492,548
44,198,744
(1) The total number of gross (or “theoretical”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.
(2) The total number of net (or “exercisable at a Shareholders' Meeting”) voting rights is calculated without taking into account shares for which voting rights have been suspended. It is released in order to ensure that the public is properly informed, in accordance with...
|
|
|
05.03.25 - 07:33
|
ABIONYX Pharma Announces Its 2024 Full-Year Results (Business Wire)
|
|
|
Improved profitability of IRIS Pharma with a net income of 6% of revenues
Extended financial visibility to the 2nd quarter of 2026 after the support of the France 2030 plan
TOULOUSE, France & LAKELAND, Mich.--(BUSINESS WIRE)--Regulatory News:
ABIONYX Pharma, (FR0012616852 - ABNX - eligible for PEA PME), a next generation biopharma company dedicated to the development of innovative biomedicines based on a recombinant apolipoprotein apoA-1 for the treatment of the most severe inflammatory diseases, today reports its 2024 full-year results as approved by the Board of Directors at its meeting of March 4, 2025. The audit procedures on the consolidated accounts have been carried out. The certification report has not been issued to date. It will be issued after the completion of the procedures required for the purposes of filing the Universal Registration Document.
Selected financial information
(as of December 31, 2024/Consolidated financial statements under IFRS)
€m
2024
2023
Revenues
4.6
4.6
Cost of goods a...
|
|
|
04.03.25 - 18:06
|
ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company′s Share Capital (Business Wire)
|
|
|
Article L233-8-II of the French Commercial Code
Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority)
PARIS--(BUSINESS WIRE)--Regulatory News:
ABIONYX Pharma (Paris:ABNX):
Market: Euronext Paris, Compartment C
ISIN code: FR0012616852
Date
Number of shares outstanding
Total voting rights
Total gross (1)
Total net (2)
February 28, 2025
34,931,012
44,492,493
44,197,190
(1) The total number of gross (or “theoretical”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.
(2) The total number of net (or “exercisable at a Shareholders' Meeting”) voting rights is calculated without taking into account shares for which voting rights have been suspended. It is released in order to ensure that the public is properly informed, in accordance ...
|
|
|
20.02.25 - 09:24
|
ABIONYX Pharma, winner of the France 2030 Plan′s “i-Démo” call for projects, awarded €8.7 million from the French government to fight against Sepsis, the 3rd leading cause of death worldwide (Business Wire)
|
|
|
TOULOUSE, France & WESTLAKE, Calif.--(BUSINESS WIRE)--ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world's only natural recombinant apoA-I, announces today that its clinical development in sepsis has been selected as part of the “i-Démo” call for projects under the France 2030 plan, operated by Bpifrance on behalf of the French government.
After 6 months of examining ABIONYX Pharma's CER-001 Sepsis project, a panel of experts was able to validate and objectify the quality of the project in its scientific, technological and clinical aspects.
The CER-001 Sepsis project represents a strategic cornerstone for ABIONYX Pharma, leveraging its unique expertise to use the only recombinant apoA-I protein in the treatment of the most severe inflammation in the human body.
The ABIONYX Pharma Sepsis project currently operates on two strategic fronts:
An integrated biomedicine approach: AB...
|
|
|
08.01.25 - 18:06
|
ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company′s Share Capital (Business Wire)
|
|
|
Article L233-8-II of the French Commercial Code
Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority)PARIS--(BUSINESS WIRE)--Regulatory News:
ABIONYX Pharma (Paris:ABNX):
Market: Euronext Paris, Compartment C
ISIN code: FR0012616852
Date
Number of shares outstanding
Total voting rights
Total gross (1)
Total net (2)
December 31, 2024
34,931,012
44,404,824
44,093,499
(1) The total number of gross (or “theoretical”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.
(2) The total number of net (or “exercisable at a Shareholders' Meeting”) voting rights is calculated without taking into account shares for which voting rights have been suspended. It is released in order to ensure that the public is properly informed, in accordance w...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
